Cogent Biosciences, Inc. 4

Arlene Morris exercised 45,510 stock options in Cogent Biosciences, Inc. and sold all resulting shares for about $1.69 million, leaving 2,773 shares owned directly.

On August 27, 2026, reporting person Arlene Morris exercised two tranches of fully vested stock options for a total of 45,510 shares of Cogent Biosciences, Inc. common stock (41,927 shares at an exercise price of $5.64 and 3,583 shares at $2.52), then immediately sold all 45,510 shares in two market transactions under a Rule 10b5-1 trading plan—42,349 shares at a weighted average price of $37.0925 and 3,161 shares at $37.5396—resulting in no remaining derivative (option) position and a residual direct ownership of 2,773 common shares. The gross value of the option exercises was approximately $119,825 based on the exercise prices, and the gross proceeds from the sales were approximately $1.69 million, implying remaining common stock holdings worth about $103,000 at the prevailing sale prices.

Filing Facts

CIK

1622229

Ticker

COGT

Form

4

Source Type

fda

Accession

0001193125-26-377001

Alert Tier

7